Prostate Cancer

Cooled laser focal therapy with the ProFocal Device showed promising cancer control in patients with localized prostate cancer.

In this episode, Amy Pearlman, MD, speaks with Phillip M. Pierorazio, MD, about integrating mindfulness and wellness into a demanding surgical career and the evolving complexities of modern prostate cancer care.

The combination was tolerable and demonstrated promising early efficacy as a 3rd-line option for patients with mCRPC.

The report highlights key trends in cancer treatment and outcomes, including detailed analyses across 3 cancer types: prostate, esophageal, and melanoma.

Gonzalgo explores how prostate cancer diagnosis and management continue to evolve.

The results highlight the early clinical potential of the device for restoring erectile function post-prostatectomy.

The ARID platform is evaluating the safety and efficacy of the Voro Urologic Scaffold in minimizing stress urinary incontinence following robot-assisted radical prostatectomy.

In this episode of The UroOnc Minute, host Adam B. Weiner, MD, speaks with Stephen J. Freedland, MD, about the role of diet and nutrition in prostate cancer risk and outcomes.

The next step is to prospectively validate the model in real-world clinical settings or within ongoing clinical trials.

The ARTISAN trial includes both 177Lu-PSMA naïve and 177Lu-PSMA experienced cohorts.

In part 2 of a 5-part series, Richard Wassersug, PhD, and Paul F. Schellhammer, MD, FACS, explore the historical, clinical, and systemic barriers to using transdermal estradiol as a treatment for prostate cancer, while highlighting its potential benefits.

In this opening segment, Richard Wassersug, PhD, and Paul F. Schellhammer, MD, FACS, discuss the origins, goals, and challenges of the Estradiol Initiative.

Treatment failure occurred in 46% of patients in the high-risk group vs 21% of patients in the low-risk group.

Enolen is currently under investigation in a phase 1 trial to assess its safety and efficacy in delivering enzalutamide locally into the prostate.

One of the most notable changes is a new thematic structure within urologic oncology.

Jim C. Hu, MD, MPH, discusses the functional advantages of a posterior approach to endopelvic neurovascular total sparing (PATENTS) robotic-assisted radical prostatectomy.

A recap of the FDA submissions and regulatory decisions in urology from December 2025.

Daniel Spratt, MD, discusses how the ArteraAI Prostate Test (Post-RP) could help guide treatment intensification decisions.

The forum underscored the importance of multidisciplinary collaboration in managing advanced prostate cancer.

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

In this episode, Timothy Daskivich, MD, joins host Adam Weiner, MD, to discuss survivorship and long-term quality-of-life considerations in prostate cancer care.

The approval is supported by data from the TRITON3 trial.

A key theme throughout the forum was the importance of assessing disease volume and clinical presentation at diagnosis.

When discussing treatment goals, clinicians underscored the importance of individualizing systemic therapy.

This episode offers practical insights for clinicians navigating complex prostate cancer cases and underscores how precision imaging and tailored radiation strategies are redefining care for patients with advanced disease.